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We report results of a phase 2, randomized, multicenter, open‐label, two‐arm study 
evaluating the safety and efficacy of eculizumab in preventing acute antibody‐ 
mediated rejection (AMR) in sensitized recipients of living‐donor kidney transplants 
requiring pretransplant desensitization (NCT01399593). In total, 102 patients under‐
went desensitization. Posttransplant, 51 patients received standard of care (SOC) 
and 51 received eculizumab. The primary end point was week 9 posttransplant treat‐
ment failure rate, a composite of: biopsy‐proven acute AMR (Banff 2007 grade II or 
III; assessed by blinded central pathology); graft loss; death; or loss to follow‐up. 
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1  | INTRODUC TION
Transplant candidates with a potential living donor may be unable to 
benefit from transplantation if they are sensitized to their donor.1,2 
Due to sensitization, approximately 4000 patients in the United 
States who have a potential living donor are waiting for a kidney trans‐
plant from a deceased donor.3 Although recent advances in desensiti‐
zation and donor pairing allow more sensitized individuals than in the 
past to receive transplants, there remains a need for new strategies 
to facilitate transplantation in many sensitized patients. Sensitization 
arises from previous exposure to allogenic human leukocyte antigens 
(HLAs) due to previous transplantation, blood transfusion, or preg‐
nancies. The presence of donor‐specific antibodies (DSAs) in kidney 
transplant recipients is a risk factor for, and correlates strongly with, 
posttransplant antibody‐mediated rejection (AMR).4‐7 Early acute 
AMR, which usually occurs within the first 9 weeks, is triggered when 
recipient DSAs bind to donor HLAs on the allograft's vascular endo‐
thelium, activating the classical complement pathway,8,9 leading to 
graft endothelial injury.10 The prevalence of early acute AMR in kid‐
ney transplant recipients with preformed DSAs has been reported to 
be as high as 60%, and it is associated with poor clinical outcomes, 
including graft loss or decreased graft survival.4,7,11‐16
A variety of desensitization protocols have been developed to fa‐
cilitate HLA‐incompatible transplantation.17‐19 Despite inconsistent 
results, plasmapheresis (PP) and intravenous immunoglobulin (IVIg) 
have become the standard of care (SOC) for desensitization.20‐24 
Antibody‐mediated rejection remains a significant problem, how‐
ever, and preventing AMR could improve both access to transplan‐
tation and outcomes.25
Eculizumab is a humanized monoclonal antibody that blocks 
cleavage of the human complement component C5 and thereby 
prevents terminal complement activation. In a single‐center pilot 
study, eculizumab lowered the incidence of acute AMR in highly 
sensitized recipients of living‐donor kidney transplants compared 
with a historic control group (AMR incidences of 7.7% and 41.2%, 
respectively).26 The primary objective of this study was to evaluate 
the safety and efficacy of eculizumab in preventing acute AMR in 
kidney transplant recipients who required desensitization.
2  | MATERIAL S AND METHODS
2.1 | Study design
This was a phase 2, randomized, multicenter, open‐label, two‐
arm, parallel‐group study and was conducted in accordance with 
the Declaration of Helsinki and the International Conference on 
Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use Guideline for Good Clinical Practice. 
The study protocol was approved by the appropriate oversight com‐
mittee for each study site (Table S1). Participants provided written 
informed consent before study entry. The study (clinicaltrials.gov 
identifier NCT01399593; EudraCT number 2010‐019630‐28) was 
sponsored by Alexion Pharmaceuticals.
Eligible patients (section 2.3) underwent pretransplant desensitiza‐
tion according to their transplant center's standard protocol (PP and 
IVIg [93.1%] or PP alone [6.9%]). All patients received immunosuppres‐
sion, prophylactic medications, and posttransplant care based on SOC 
at each site (Figure 1). After desensitization and approval for transplan‐
tation, participants were randomized in a one‐to‐one ratio to receive 
either eculizumab (Soliris, Alexion Pharmaceuticals, Inc., Boston, MA; 
eculizumab group), or standard posttransplant care only (SOC group), 
which could have included any combination of PP and/or IVIg, for 
9 weeks from the day of transplantation (Figure 1). Randomization, via 
a web‐based randomization system, was conducted by Sharp Clinical 
Services (Phoenixville, PA). Randomization was stratified by the pre‐
transplant desensitization protocol used but not by site.
Patients in the eculizumab group received one dose of eculi‐
zumab (1200 mg) approximately 1 hour before reperfusion of the 
Eculizumab was well tolerated with no new safety concerns. No significant difference 
in treatment failure rate was observed between eculizumab (9.8%) and SOC (13.7%; 
P = .760). To determine whether data assessment assumptions affected study out‐
come, biopsies were reanalyzed by central pathologists using clinical information. The 
resulting treatment failure rates were 11.8% and 21.6% for the eculizumab and SOC 
groups, respectively (nominal P = .288). When reassessment included grade I AMR, 
the treatment failure rates were 11.8% (eculizumab) and 29.4% (SOC; nominal 
P = .048). This finding suggests a potential benefit for eculizumab compared with 
SOC in preventing acute AMR in recipients sensitized to their living‐donor kidney 
transplants (EudraCT 2010‐019630‐28).
K E Y W O R D S
clinical research/practice, complement biology, donors and donation: living, 
immunosuppressant ‐ fusion proteins and monoclonal antibodies, kidney transplantation/
nephrology, rejection: antibody‐mediated (ABMR), sensitization
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allograft (day 0) and then for 9 weeks posttransplant according to 
the dosing regimen described in Figure 1. For‐cause allograft biop‐
sies were performed if there were clinical signs of allograft dysfunc‐
tion with or without elevation of DSA based upon at least one of the 
following criteria, from baseline (day of transplantation): a decrease 
in serum creatinine (SCr) of less than 10% per day on 3 consecutive 
days in the first week posttransplant; an increase in SCr; proteinuria; 
oliguria; or clinical suspicion of AMR. Protocol‐mandated biopsies 
were to be performed postreperfusion (intraoperative), at day 14 
posttransplant, and at months 3, 12, and 36 posttransplant.
2.2 | Pathology analyses and patient management
All biopsies were processed and analyzed by each transplant center's 
pathology laboratory (referred to as local pathology). Local patholo‐
gists had access to clinical information and were involved in patient 
management decisions including the diagnosis and treatment of 
acute AMR. To reduce variability in evaluations between multiple 
pathologists, a panel of three independent pathologists (two primary 
pathologists and one adjudicator for cases on which the primary 
pathologists disagreed) conducted a review of all biopsies blinded 
to treatment, local pathology diagnoses, clinical information, DSA 
status, and C4d status by immunofluorescence, for study end point 
evaluation only, using a standardized process established before 
study initiation (central pathology analyses). The central pathologists 
scored whole images of light microscopic slides from local pathology 
and performed immunohistochemistry to determine C4d status.
Patients from both groups diagnosed with acute AMR were initially 
treated with PP and/or IVIg. Patients could subsequently be treated 
with eculizumab for up to 9 weeks (minimum of 5 weeks), at the dis‐
cretion of the principal investigator. Patients in the eculizumab group 
who were treated with PP received supplemental eculizumab (600 mg) 
within 1 hour to maintain therapeutic eculizumab levels.27
2.3 | Study population
Patients were recruited from 41 sites in 10 countries in Europe, 
North America, and Australia.
Patients aged 18 years or older were eligible for inclusion if they 
had stage IV or V chronic kidney disease and were to receive a kid‐
ney transplant from a living donor to whom they were sensitized, 
and therefore required pretransplant desensitization. The presence 
of DSAs was determined by single‐antigen bead assay (Luminex 
LABScreen, One Lambda, CA) performed by the central laboratory. 
In addition to a history of previous exposure to HLAs and the pres‐
ence of DSAs, eligible patients had to have either a positive comple‐
ment‐dependent cytotoxicity (CDC) crossmatch (current or historic), 
or a negative CDC with a positive B‐cell flow crossmatch (BFXM) and/
or T‐cell flow crossmatch (TFXM; according to local thresholds) before 
desensitization.
Women of childbearing potential were required to have a 
negative pregnancy test and use effective contraception for 
5 months after their last dose of eculizumab. All participants 
who were not vaccinated against Neisseria meningitidis on study 
entry received the vaccination at least 14 days before their first 
dose of eculizumab and a booster 30 days after their first vacci‐
nation. Patients who had been vaccinated against N. meningitidis 
before enrollment received a booster. Prophylactic antibiotics 
could be provided during eculizumab treatment, according to 
local practice.
2.4 | Primary efficacy end point
The primary end point was the week 9 posttransplant treatment fail‐
ure rate, which was a composite of the occurrence of: biopsy‐proven 
AMR (Banff 2007 grade II or III); graft loss; patient death; or loss to 
follow‐up (including discontinuation).
F I G U R E  1   Study design. AMR, antibody‐mediated rejection; IVIg, intravenous immunoglobulin; MMF, mycophenolate mofetil; PP, 
plasmapheresis; SOC, standard of care; TAC, tacrolimus
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Diagnosis of acute AMR for the primary end point was based on 
review of for‐cause kidney biopsies performed by the central pathol‐
ogists according to Banff 2007 criteria, which included the require‐
ment for C4d+ staining for diagnosis of acute AMR.23,28 Grade I AMR 
was not included because it is impossible to distinguish it from acute 
tubular injury with incidental C4d deposition using only pathological 
criteria. Because only grades II and III, acute AMR were included in 
the primary end point, this was defined as the presence of circulating 
DSAs and morphologic evidence of acute tissue injury as determined 
by the central pathologists.
2.5 | Sensitivity and post hoc analyses
A prespecified sensitivity analysis of local pathologists’ biopsy re‐
sults was performed and compared with the primary analysis of 
central pathologists’ results. To explore possible reasons for the dis‐
cordance observed between central and local pathology results, ad‐
ditional analyses were performed. As grade I AMR was not included 
in the primary analysis, a post hoc sensitivity analysis of local and 
central pathology results including grade I acute AMR was con‐
ducted, recognizing that grade I acute AMR is also a pattern of early 
acute AMR.
A reassessment of biopsies by the central pathologists was also 
performed for all grades of AMR in which they remained blinded to 
treatment but were provided with relevant clinical information for 
each patient to more closely simulate real clinical practice.
In addition, post hoc analyses were performed to assess agree‐
ment between the original central pathology biopsy results and the 
local pathology results, and the reassessed central results and the local 
results, including grade I AMR, using a kappa measure of agreement.
2.6 | Safety end points
Safety was assessed throughout the study and is reported for until 
each patient's final study visit. Safety assessments included moni‐
toring of all treatment‐emergent adverse events (TEAEs) and serious 
adverse events (SAEs).
2.7 | Statistical methods
All patients who received a living‐donor kidney transplant and their ran‐
domized treatment were included in the efficacy and safety analyses.
The expected background rate of treatment failure for the 
SOC arm was estimated to be 36.3%, based on a pooled analy‐
sis of published AMR incidence, although it is recognized that the 
definition of sensitized patients varies between centers.21,29‐32 
The expected treatment failure rate at week 9 posttransplant 
(primary end point) in the eculizumab group was estimated from 
the pilot study of highly sensitized patients (with baseline BFXM 
mean channel shift [mcs] of over 320) to be 10%.26 These esti‐
mates were used to determine sample size and power. This study 
was powered at over 90% based on these expected failure rates. 
The observed difference in the treatment failure rates at week 
9 posttransplant between the eculizumab and the SOC groups 
was calculated with a 95% confidence interval (CI) using an exact 
unconditional method.33 The null hypothesis was tested using 
F I G U R E  2   Patient disposition. aFailed screening (n, %): did not meet inclusion/exclusion criteria (62, 22.5%), physician decision (n = 13, 
4.7%), adverse event (3, 1.1%), withdrawal by patient (3, 1.1%), death (1, 0.4%), other (56, 20.4%). bScreened but not randomized (n, %): failed 
desensitization (18, 6.5%), adverse event (4, 1.5%), enrollment failure (3, 1.2%), failed inclusion/exclusion criteria (1, 0.4%), withdrawal by 
patient (1, 0.4%), other (6, 2.2%). cDid not receive treatment (n, %): donor changed mind (1, 0.4%), issues with donor kidney (1, 0.4%)
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Fisher's exact test,34 with a two‐sided P value of .05 or below indi‐
cating statistical significance.
3  | RESULTS
3.1 | Patient disposition and characteristics
The first patient was screened on November 2, 2011. The study was 
terminated early (November 13, 2015) because of failure to meet 
the primary efficacy end point. The date of last patient contact was 
February 11, 2016.
In total, 275 patients were screened for study inclusion, of whom 
104 (37.8%) were randomized (Figure 2). Of these, 102 (98.1%) re‐
ceived a transplant from a living donor and their randomized ther‐
apy (eculizumab or SOC alone) and were analyzed. Randomized and 
treated patients were equally distributed between the eculizumab 
group (n = 51) and the SOC group (n = 51) (Figure 1).
Descriptive recipient characteristics are in Tables 1 and 2. Baseline 
demographics were generally similar between the two treatment 
groups, although there were more women in the eculizumab group 
(72.5%) than in the SOC group (58.8%). Patients in the eculizumab 
group had a slightly shorter median (range) duration of pretransplant 
chronic renal failure (89.0 [3‐385] months) compared with the SOC 
group (139.0 [7‐593] months). More patients in the eculizumab group 
(36/51; 70.6%) than in the SOC group (28/51; 54.9%) had a positive 
CDC crossmatch during screening. According to central laboratory 
results, 94.1% of all patients were positive for class I or class II DSA 
before transplantation. The study population's median (range) DSA 
was 12 737.5 (932‐85 358) mean fluorescence intensity (Table 3).
All patients in the eculizumab group received at least one dose of 
eculizumab. By week 9, all except two of these patients had received 
at least nine infusions. Complete inhibition of terminal complement 
was achieved at all visits in ≥95% of patients. Subsequently, six pa‐
tients (11.2%) in the eculizumab group received additional doses of 
Characteristic, unit 
Statistic or category
Eculizumab  
(N = 51)
SOC 
(N = 51)
Total 
(N = 102)
Age, y
Mean (SD) 45.0 (14.48) 40.9 (13.24) 43.0 (13.96)
Median (min‐max) 45.0 (18‐75) 37.0 (19‐79) 42.5 (18‐79)
Age group, n (%)
<65 y 47 (92.2) 49 (96.1) 96 (94.1)
≥65 y 4 (7.8) 2 (3.9) 6 (5.9)
Sex, n (%)
Male 14 (27.5) 21 (41.2) 35 (34.3)
Female 37 (72.5) 30 (58.8) 67 (65.7)
Racea , n (%)
White 37 (72.5) 36 (70.6) 73 (71.6)
Black or African‐American 6 (11.8) 6 (11.8) 12 (11.8)
Asian 2 (3.9) 3 (5.9) 5 (4.9)
Duration of chronic renal failure before transplantation, mob 
Mean (SD) 124.6 (99.1) 171.0 (130.6) 147.8 (117.7)
Median (min‐max) 89.0 (3‐385) 139.0 (7‐593) 131.9 (3‐593)
Patient on dialysis at the time of transplantation? n (%) 
Yes 46 (90.2) 46 (90.2) 92 (90.2)
No 5 (9.8) 5 (9.8) 10 (9.8)
Duration of dialysis before transplantation, moc 
n 46 46 92
Mean (SD) 95.9 (100.38) 128.0 (112.74) 112.0 (107.37)
Median (min‐max) 40.3 (2‐361) 77.0 (5‐377) 58.1 (2‐377)
Max, maximum; min, minimum; SD, standard deviation; SOC, standard of care.
aCollection of race data is not permitted in some European countries. 
bDuration (mo) = ([date of transplantation or date of first dose of treatment]‐[date of chronic renal 
failure])/30.4. 
cDuration (mo) = ([date of transplantation or date of first dose of treatment]‐[date of first 
dialysis])/30.4. 
TA B L E  1   Baseline characteristics
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eculizumab for the treatment of AMR that was diagnosed after the 
first 9 weeks.
Twenty‐two patients (43.1%) in the SOC group received at least 
one dose of eculizumab for treatment of AMR during the study, in‐
cluding 14 (27.5%) who developed AMR and received eculizumab for 
its treatment during the initial 9 weeks of the study, at the investiga‐
tor's discretion. One additional patient in the SOC group developed 
acute AMR during the first 9 weeks posttransplant but was never 
treated with eculizumab.
Most patients completed the month‐12 visit: 46 (90.2%) and 47 
(92.2%) in the eculizumab and SOC groups, respectively. At the time 
of study termination, 87 patients had completed the month‐18 visit. 
Mean duration (± standard deviation [SD]) of participation in the 
study was 28.6 (±9.58) and 26.9 (±8.77) months for the eculizumab 
and SOC groups, respectively.
3.2 | Treatment outcomes
Treatment failure (composite primary end point) was observed in five 
patients (9.8%) in the eculizumab group and seven patients (13.7%) 
in the SOC group in the first 9 weeks posttransplant (Table 4). Acute 
AMR (grade II or III) occurred in five patients in the eculizumab group 
at a mean of 19.4 (SD 11.33) days posttransplant and in five patients 
in the SOC group at a mean of 16.6 (SD 12.99) days posttransplant. 
Treatment failure rates were not significantly different between 
the two groups (P = .760; difference −3.9%; 95% CI −23.9, 16.3). At 
month 12, there was no significant difference in treatment failure 
rates between the eculizumab group (10/51 patients, 19.6%) and the 
SOC group (9/51 patients, 17.6%) (P = .800; difference−2.0%; 95% 
CI −18.2, 22.0).
Over 90% of protocol‐mandated biopsies showed no transplant 
glomerulopathy (chronic glomerulopathy grade 0) through month 12 
(Table S2).
Estimated glomerular filtration rates and creatinine levels at 
baseline, week 9, and month 12 are presented in Table S3.
Graft losses occurred in both groups, but the small number of 
these events limits further interpretation. By week 9, there were no 
graft losses in the eculizumab group and three graft losses in the 
SOC group, which were attributed to a technical complication, acute 
AMR, and graft vascular dysfunction. By month 12, two patients 
in the eculizumab group had experienced graft loss owing to acute 
renal failure with unknown cause and recurrent anti‐glomerular 
basement membrane disease. There was one additional case of graft 
loss in the SOC group by month 12, which was due to acute AMR.
No significant differences in patient or graft survival were observed 
between treatment groups. Patient survival posttransplant through 
month 36 was 98.0% (95% CI 86.9‐99.7) for both the eculizumab and 
SOC groups. The proportion of grafts that survived through month 
36 was 91.8% (95% CI 79.7‐96.9) for the eculizumab group and 78.5% 
(95% CI 59.3‐89.4) for the SOC group (Figures 3 and S1).
3.3 | Sensitivity analyses
3.3.1 | Comparison of local and central pathology 
results for grades II and III AMR
The treatment failure rate determined by local pathology was quite 
different from the central pathology results. There was an overall 
higher incidence of acute AMR (grades II and III) and correspond‐
ing treatment failure rate reported by local pathology (eculizumab 
13.7%; SOC 29.4%; P = .091) than by central pathology (eculizumab 
9.8%; SOC 13.7%; P = .760) (Table S4).
3.3.2 | Comparison of local and central pathology 
results for grades I, II, and III AMR
To understand whether the differences between the central and 
local pathology results were primarily due to differences in the in‐
terpretation of grades I and II AMR, a post hoc sensitivity analysis 
of treatment failure rates including grade I AMR was conducted 
for both central and local pathology results. This analysis also 
showed discordance between local pathology (eculizumab 19.6%; 
SOC 41.2%; P = .031) and central pathology (eculizumab 9.8%; SOC 
17.6%; P = .389) (Table S4). Of note, most cases of acute AMR in this 
study were grade I or II as interpreted by the local and central pa‐
thologists (Table S5).
Parameter, unit  
Statistic or category
Eculizumab 
(N = 51)
SOC  
(N = 51)
Total  
(N = 102)
Patients who had a previous 
kidney transplant, n (%)
24 (47.1) 35 (68.6) 59 (57.8)
Number of previous kidney transplants, n (%)
1 17 (33.3) 23 (45.1) 40 (39.2)
2 6 (11.8) 8 (15.7) 14 (13.7)
>3 1 (2.0) 4 (7.8) 5 (4.9)
Type of previous transplant, n (%)
Live donor 10 (19.6) 15 (29.4) 25 (24.5)
Deceased donor 14 (27.5) 20 (39.2) 34 (33.3)
SOC, standard of care.
TA B L E  2   Previous kidney 
transplantation information
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3.3.3 | Central and local pathology 
agreement analysis
Given the observed differences between the treatment failure rates 
reported by the central and local pathologists, an agreement analysis 
of all pathology results was undertaken retrospectively.
The AMR grades for the initial evaluations by local and central 
pathology of each of the 241 per‐protocol and for‐cause biopsies 
assessed during the 9‐week primary end point period are shown in 
Table S5. The kappa coefficient measures the level of agreement be‐
tween the respective laboratories’ gradings, accounting for expected 
agreement by chance. Most biopsies (75.5%) were assessed to be 
negative for acute AMR by both central and local pathologists. There 
was, however, generally poor agreement between the central and 
local pathologists for biopsies scored as grade I, II, or III acute AMR. 
The kappa score overall was 0.225, which would be considered only 
TA B L E  3   Central laboratory baseline immunology information
Parameter, unit 
Statistic or category
Eculizumab  
(N = 51)
SOC 
(N = 51)
Total 
(N = 102)
CDC/FXM status, n (%)a 
CDC‐negative/FXM‐negative 12 (23.5) 18 (35.3) 30 (29.4)
CDC‐negative/FXM‐positive 3 (5.9) 3 (5.9) 6 (5.9)
CDC‐positive/FXM‐negative 24 (47.1) 15 (29.4) 39 (38.2)
CDC‐positive/FXM‐positive 12 (23.5) 13 (25.5) 25 (24.5)
Missing CDC/FXM status 0 (0.0) 2 (3.9) 2 (2.0)
B‐cell flow crossmatch, mcs
n 50 48 98
Mean (SD) 196.4 (115.68) 193.4 (107.51) 194.9 (111.18)
Median (min‐max) 192.9 (−29‐418) 169.6 (1‐457) 184.4 (−29‐457)
T‐cell flow crossmatch, mcs
n 49 48 97
Mean (SD) 140.7 (107.71) 170.1 (122.76) 155.2 (115.74)
Median (min‐max) 125.0 (−16‐383) 160.3 (−8‐431) 149.8 (−16‐431)
DSA overall (class I/II), n (%)
Positive 49 (96.1) 47 (92.2) 96 (94.1)
Negative 1 (2.0) 2 (3.9) 3 (2.9)
Missing/unknown 1 (2.0) 2 (3.9) 3 (2.9)
DSA class I, n (%)
Positive 43 (84.3) 39 (76.5) 82 (80.4)
Negative 5 (9.8) 10 (19.6) 15 (14.7)
Missing/unknown 3 (5.9) 2 (3.9) 5 (4.9)
DSA class II, n (%)
Positive 33 (64.7) 33 (64.7) 66 (64.7)
Negative 16 (31.4) 13 (25.5) 29 (28.4)
Missing/unknown 2 (3.9) 5 (9.8) 7 (6.9)
Total number of DSAs
n 50 48 98
Mean (SD) 2.7 (1.41) 2.8 (1.51) 2.7 (1.45)
Median (min‐max) 3.0 (1‐6) 3.0 (1‐7) 3.0 (1‐7)
Immunodominant DSA (highest single DSA), MFI
n 50 48 98
Mean (SD) 8135.0 (4048.08) 8740.7 (4289.97) 8431.7 (4157.87)
Median (min‐max) 8148.5 (932‐16 177) 8985.0 (1218‐18 973) 8620.5 (932‐18 973)
Total DSA, MFI
n 50 48 98
Mean (SD) 15 394.7 (14 163.78) 17 469.8 (12 573.44) 16 411.1 (13 380.16)
Median (min‐max) 11 921.0 (932‐85 358) 15 031.0 (1218‐64 254) 12 737.5 (932‐85 358)
CDC, complement‐dependent cytotoxicity; DSA, donor‐specific antibody; FXM, flow crossmatch (B‐ or T‐cell); max, maximum; mcs, mean channel 
shift; MFI, mean fluorescence intensity; min, minimum; SD, standard deviation; SOC, standard of care.
aCDC status was CDC status during screening, not historic CDC status; FXM‐positive status was based on either B‐ or T‐cell FXM values >285 mcs. 
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slight agreement.35 Discordance in acute AMR diagnoses between 
the individual central pathologists was also observed (Table S6).
3.3.4 | Reassessment of central pathology analyses
A major difference between local and central pathology analyses was 
that only local pathologists had access to clinical information related to 
the biopsies. Because acute AMR is a clinicopathologic diagnosis, ex‐
perts including pathologists recommended a reassessment of the biop‐
sies by the central pathologists using the relevant clinical information 
on each patient (Table S7) while remaining blinded to treatment arm.
This reassessment improved agreement between local and cen‐
tral pathologists (Tables 5 and S5) to a kappa score of 0.496 (con‐
sidered moderate agreement).35 After reassessment of 109 biopsies, 
the number categorized as grade II or III AMR increased from 10 to 
15. When grade I AMR was included, there were 12 cases before 
reassessment compared with 19 cases after reassessment, including 
four additional cases of grade I AMR and four additional cases of 
grade II/III AMR. Of the 10 patients identified as having AMR by the 
original central biopsy assessment, nine were also diagnosed during 
the reassessment. Importantly, 12/15 (80%) and 16/19 (84%) of the 
patients diagnosed with AMR in the central pathology reassessment 
had also been diagnosed with AMR excluding and including grade I, 
respectively, by the local biopsy assessment.
This post hoc reassessment revealed treatment failure rates of 
11.8% and 21.6% (P = .288) for the eculizumab and SOC treatment 
groups, respectively (Table 5). Inclusion of grade I AMR resulted in a 
larger observed treatment difference between eculizumab and SOC 
for both central pathology (11.8% and 29.4%, respectively; nominal 
P = .048) and local pathology (19.6% and 41.2%, respectively; nom‐
inal P = .031). Among the 25 patients who were positive for both 
CDC and BFXM or TFXM (>285 mcs) during screening, nine were 
diagnosed with AMR of grade I, II, or III according to this reassess‐
ment: 16.7% of this subgroup who received eculizumab and 53.8% 
of this subgroup who received SOC experienced AMR (Table S8).
3.4 | Safety assessments
During the study, all patients experienced at least one TEAE and 
most patients had at least one SAE (Tables 6 and S9). The incidence 
of SAEs was 94.1% in the SOC group and 84.3% in the eculizumab 
group.
There were no meningococcal infections during this study. 
Twelve patients did not complete the study owing to safety‐related 
reasons (adverse events or death). One patient in each group died 
during the study. In the eculizumab group, a 45‐year‐old woman died 
of bacterial sepsis on day 38. She experienced clinically significant 
infections that were considered by the investigator to be possibly 
related to eculizumab and were attributed to a bowel perforation 
following a kidney biopsy and her posttransplant immunosuppres‐
sive burden. In the SOC group, a 43‐year‐old woman who received 
no eculizumab died on day 5 of cardiac arrest, which was considered 
by the investigator to be due to preexisting cardiac disease.
By month 12, a total of 12 patients (23.5%) in the SOC group 
and 11 patients (21.6%) in the eculizumab group had experienced 
TA B L E  4   Primary end point as determined by the central pathologists
Eculizumab (N = 51) 
n (%)
SOC (N = 51) 
n (%)
Difference  
(exact 95% CI) P value
Composite primary end point
Treatment failure rate (including grades II 
and III AMR)
5 (9.8) 7 (13.7) −3.9% 
(−23.9, 16.3)
.760
Composite primary end point components
Acute AMR (grade II or III) 5 (9.8) 5 (9.8)
Graft loss 0 (0.0) 3 (5.9)
Death 1 (2.0) 1 (2.0)
Loss to follow‐up 0 (0.0) 2 (3.9)
AMR, antibody‐mediated rejection; SOC, standard of care.
F I G U R E  3   Graft survival through 36 months. Graft survival time 
was defined as the time from transplantation until the date of death 
or date of graft loss. A patient who did not die or have graft loss 
was censored at the time of last contact. *P = .209 at 36 months. 
SOC, standard of care
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biopsy‐proven acute cellular rejection (this was detected by month 3 
in most [65.2%] of these cases).
4  | DISCUSSION
Transplant candidates who are sensitized to their potential living do‐
nors may be unable to benefit from transplantation. Although paired 
kidney exchange has increased access to living‐donor transplanta‐
tion in sensitized individuals with a calculated panel‐reactive anti‐
body of ≥80%, the absolute number of transplants it has facilitated 
is small (Schinstock et al., 2019, unpublished data). A need therefore 
remains for other novel strategies, such as complement inhibition, to 
facilitate kidney transplantation in sensitized individuals.38
This study was conducted in a population of kidney transplant 
recipients who were at high risk of acute AMR because they were 
sensitized to their living donors. There was no significant difference 
in treatment failure rate (including grade II or III acute AMR) between 
the eculizumab and SOC groups. In a post hoc analysis including 
grade I AMR, the treatment failure rate was lower in the eculizumab 
group than in the SOC group, suggesting that terminal complement 
inhibition may prevent early acute AMR. The treatment failure rate 
(including grade II or III acute AMR) in the eculizumab group in this 
study was similar to the rates estimated from a previously published 
pilot study (10%),26 and from a single‐arm study of sensitized recipi‐
ents of deceased‐donor kidney transplants who received eculizumab 
for AMR prevention without pretransplant desensitization therapy 
(<10%),37 compared with the expected rate of 30% to 40% reported 
in the literature.
Graft survival at 36 months posttransplant for eculizumab‐
treated patients was 91.8% compared with 78.5% in the SOC group, 
which was the expected rate for sensitized recipients. Although this 
difference is not statistically significant, the direction of the effect 
is promising, considering the long duration of pretransplant dialysis 
experienced by the patients in this study (mean, 112 months) and 
the well‐known inverse relationship between patient survival and 
time on dialysis.
A post hoc analysis of subgroups based on CDC and FXM base‐
line status (Table S8) revealed that the rate of AMR was higher in 
patients who were both CDC‐positive and FXM‐positive than in the 
TA B L E  5   Treatment failure rate (reassessed central and local pathology, with and without grade I antibody‐mediated rejection included)
AMR Location End point
Eculizumab 
(N = 51) n (%)
SOC 
(N = 51) n (%)
Difference 
(exact 95% CI) P value
Grade II or III acute 
AMR only
Centrala ,b  Treatment failure 6 (11.8) 11 (21.6) –9.8% 
(–29.6, 10.5)
.288
AMR 6 (11.8) 9 (17.6)
Graft loss 1 (2.0) 4 (7.8)
Death 1 (2.0) 1 (2.0)
Loss to follow‐up 0 (0.0) 0 (0.0)
Localc  Treatment failure 7 (13.7) 15 (29.4) –15.7% 
(–35.1, 4.7)
.091
AMR 7 (13.7) 12 (23.5)
Graft loss 1 (2.0) 4 (7.8)
Death 1 (2.0) 1 (2.0)
Loss to follow‐up 0 (0.0) 0 (0.0)
Grade I, II, or III 
acute AMR
Centrala ,b  Treatment failure 6 (11.8) 15 (29.4) –17.7% 
(–37.0, 2.7)
.048
AMR 6 (11.8) 13 (25.5)
Graft loss 1 (2.0) 4 (7.8)
Death 1 (2.0) 1 (2.0)
Loss to follow‐up 0 (0.0) 0 (0.0)
Localc  Treatment failure 10 (19.9) 21 (41.2) –21.6% 
(–40.6, –1.2)
.031
AMR 10 (19.6) 18 (35.3)
Graft loss 1 (2.0) 4 (7.8)
Death 1 (2.0) 1 (2.0)
Loss to follow‐up 0 (0.0) 0 (0.0)
AMR, antibody‐mediated rejection; CI, confidence interval; SOC, standard of care.
aReassessed using clinical information available to local pathologists. 
bIncluding initial results for 132 biopsies considered negative for acute AMR by the local and both central pathologists that were not reassessed. 
cInitial biopsy results. 
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other baseline immune status subgroups. This suggests that there 
may be different subtypes of acute AMR in these subgroups. For 
the CDC‐positive/FXM‐positive subgroup, terminal complement 
activity may be primarily responsible for tissue injury, while for the 
other subgroups, downstream complement‐initiated activities may 
contribute more to tissue injury.
The treatment failure rate in this study was lower than expected 
under SOC (13.7% compared with 36.3% estimated from the litera‐
ture). One potential explanation for this is because only grades II and 
III acute AMR were initially considered a treatment failure, and not 
grade I. The treatment failure rate in the SOC group increased from 
13.6% to 17.6% when grade I AMR was included in the post hoc anal‐
ysis. The Banff classification grades of acute AMR reflect patterns 
of injury and not necessarily clinical severity, and common patterns 
of early acute AMR, for example acute tubular necrosis‐like minimal 
inflammation, were excluded with grade I AMR.7 Diagnosis of early 
grade I acute AMR is clinically meaningful because it may progress 
to severe graft injury and loss.12 In practice, transplant clinicians fre‐
quently consider AMR to be present or absent without distinguish‐
ing between grades, and they therefore treat patients with grade I 
AMR in the context of diminished graft function. In patients receiv‐
ing prophylactic eculizumab, however, the interpretation of grade I 
acute AMR may be difficult without information on renal function, 
as normal grafts with effective terminal complement inhibition can 
still show C4d deposition in peritubular capillaries if there are high 
levels of circulating DSA. Further, the difference between grades I 
and II acute AMR may be subject to interpretation and bias, because 
of limited reproducibility of capillaritis and glomerulitis scores be‐
tween pathologists.38,39 The majority rules method (as implemented 
in this study by involvement of the adjudicating central pathologist) 
has been shown to reduce variation in Banff scoring.40
Secondly, biopsy diagnoses of grade II/III acute AMR were orig‐
inally made by central pathologists without clinical information. In a 
typical clinical setting, however, pathologists have access to all rele‐
vant clinical information, including serum DSA levels and creatinine 
TA B L E  6   Incidence of serious treatment‐emergent adverse 
events that occurred in at least 3% of patients in either treatment 
group throughout the study (until each patient's final study visit)
MedDRA system organ class 
Preferred term
Eculizumab 
(N = 51) 
n (%)
SOC  
(N = 51) 
 
Patients with any serious TEAE 43 (84.3) 48 (94.1)
Immune system disorders 22 (43.1) 28 (54.9)
Kidney transplant rejection 22 (43.1) 28 (54.9)
Infections and infestations 32 (62.7) 25 (49.0)
Escherichia urinary tract 
infection bacterial
4 (7.8) 6 (11.8)
Urinary tract infection 2 (3.9) 7 (13.7)
Pneumonia 3 (5.9) 4 (7.8)
Pyelonephritis 4 (7.8) 2 (3.9)
Urosepsis 4 (7.8) 2 (3.9)
Bronchitis 2 (3.9) 3 (5.9)
Cellulitis 2 (3.9) 2 (3.9)
Gastroenteritis 0 (0.0) 4 (7.8)
Gastroenteritis viral 1 (2.0) 2 (3.9)
Urinary tract infection 
bacterial
2 (3.9) 1 (2.0)
Urinary tract infection 
enterococcal
1 (2.0) 2 (3.9)
Lower respiratory tract 
infection
2 (3.9) 0 (0.0)
Gastrointestinal disorders 9 (17.6) 17 (33.3)
Diarrhea 3 (5.9) 8 (15.7)
Pancreatitis acute 1 (2.0) 2 (3.9)
Injury, poisoning, and 
procedural complications
9 (17.6) 12 (23.5)
Post procedural hemorrhage 1 (2.0) 3 (5.9)
Delayed graft function 2 (3.9) 1 (2.0)
Incisional hernia 2 (3.9) 1 (2.0)
Post procedural hematuria 0 (0.0) 2 (3.9)
Wound dehiscence 0 (0.0) 2 (3.9)
Renal and urinary disorders 9 (17.6) 12 (23.5)
Acute kidney injury 2 (3.9) 3 (5.9)
Hematuria 1 (2.0) 2 (3.9)
Hydronephrosis 2 (3.9) 3 (5.9)
Vascular disorders 8 (15.7) 9 (17.6)
Deep vein thrombosis 2 (3.9) 0 (0.0)
Lymphocele 3 (5.9) 5 (9.8)
Blood and lymphatic system 
disorders
3 (5.9) 7 (13.7)
Anemia 1 (2.0) 2 (3.9)
General disorders and 
administration site conditions
6 (11.8) 1 (2.0)
Chest pain 2 (3.9) 0 (0.0)
Edema peripheral 2 (3.9) 0 (0.0)
(Continues)
MedDRA system organ class 
Preferred term
Eculizumab 
(N = 51) 
n (%)
SOC  
(N = 51) 
 
Nervous system disorders 4 (7.8) 3 (5.9)
Headache 0 (0.0) 2 (3.9)
Migraine 2 (3.9) 0 (0.0)
Cardiac disorders 3 (5.9) 3 (5.9)
Cardiac failure 0 (0.0) 2 (3.9)
Investigations 5 (9.8) 1 (2.0)
Blood creatinine increased 3 (5.9) 1 (2.0)
MedDRA, Medical Dictionary for Regulatory Activities; SOC, standard 
of care; TEAE, treatment‐emergent adverse event.
Both fatal and nonfatal serious TEAEs are included in this table. System 
organ classes are sorted by decreasing frequency for the combined 
incidence. Patients with more than one event within a system organ 
class are counted only once.
TA B L E  6   (Continued)
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increases. When the central pathologists reassessed biopsies using 
clinical information, but still blinded to treatment, the treatment fail‐
ure rate including grade I AMR in the SOC group, increased from 
17.6% to 29.4%. In addition, the treatment failure rate including 
grade I AMR in the SOC group, assessed by local pathology using 
both biopsies and clinical information, was 41.2% Both these reas‐
sessment rates are close to the expected rate of 36.3% estimated 
from the literature review. These findings demonstrate the impor‐
tance of clinical information in AMR diagnosis.
Another potential explanation for the low treatment failure rate 
in the SOC group is differences in enrollment criteria between sites, 
particularly in DSA inclusion thresholds and crossmatch definitions, 
which may have affected acute AMR rates, as patients with higher 
baseline DSA levels are generally at higher risk of early acute AMR.4‐7
It is interesting that, despite treatment failure rates of up to 
41.2%, the rate of transplant glomerulopathy found on 1‐year sur‐
veillance biopsies was low (<10%) compared with previous studies 
of positive crossmatch kidney transplant recipients (44% to 63% at 
12‐24 months posttransplant).41,42
The types of TEAEs observed in this study were characteristic of 
transplant populations and were similar in the two treatment groups. 
All patients received immunosuppressive agents during the study, 
which increased their risk of infections. Overall, the incidence of se‐
rious TEAEs was numerically higher in the SOC group, while that of 
serious infections was numerically higher in the eculizumab group. 
The safety profile of eculizumab was consistent with that reported 
in eculizumab's other approved indications, atypical hemolytic ure‐
mic syndrome43,44 and paroxysmal nocturnal hemoglobinuria,45 over 
10 years.
The main limitations of this study were its open‐label design and 
the assessment of biopsies without clinical information or inclusion 
of clinically relevant grade I AMR to diagnose AMR for the primary 
end point. In addition, no analyses of the pathological findings or 
of long‐term outcomes were conducted on the patients in the SOC 
group who received eculizumab for AMR treatment within 9 weeks 
of transplantation.
Eculizumab use has previously been shown to result in a lower 
AMR incidence in the first 3 months posttransplant in kidney re‐
cipients sensitized to their living donors than in a well‐matched his‐
torical control group (7.7% [2/26] and 41.2% [21/51], respectively; 
P = .0031).26 Eculizumab may prove to be most effective in the early 
posttransplant phase, because this is when grafts are more likely to 
be subjected to high serum DSA levels (associated with complement‐
fixing DSA); biopsies from this period tend to show complement 
deposition (C4d+).7,46 Together, these data suggest that eculizumab 
has the potential to have meaningful positive effects on prevent‐
ing acute AMR in kidney transplant recipients who are sensitized to 
their donors, particularly when all grades of AMR are considered. 
This is supported by the recent finding that complement‐activating 
DSA‐mediated kidney allograft rejection can be abrogated by ecu‐
lizumab.47 The effects of terminal complement inhibition by eculi‐
zumab need to be confirmed in future trials that address the issues 
raised here. Such trials should include uniform inclusion criteria 
based on current understanding of histocompatibility risk factors 
(for example, standardized DSA thresholds and stratification accord‐
ing to the complement‐binding capacity of DSAs),48 recognize acute 
AMR as a clinicopathologic diagnosis, and address issues affecting 
the reproducibility of AMR diagnosis. Importantly, in future studies, 
attempts should be made to understand which histocompatibility 
tests and other biomarkers are most accurate in identifying sensi‐
tized patients who would benefit most from terminal complement 
inhibition by eculizumab.
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